846
Participants
Start Date
July 29, 2025
Primary Completion Date
December 31, 2029
Study Completion Date
January 31, 2030
Dexmedetomidine
Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
Placebo Control
Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
NOT_YET_RECRUITING
Fraser Health Authority, Surrey
NOT_YET_RECRUITING
Brockville General Hospital, Brockville
RECRUITING
St. Joseph's Healthcare Hamilton, Hamilton
NOT_YET_RECRUITING
Juravinski Hospital and Cancer Centre, Hamilton
NOT_YET_RECRUITING
North York General Hospital, Toronto
NOT_YET_RECRUITING
Sinai Health System, Toronto
Collaborators (1)
Population Health Research Institute
OTHER
St. Joseph's Healthcare Hamilton
OTHER